BioWorld

Feb. 21, 2007

View Archived Issues

Shire Buying Vyvanse Partner New River For $64 Per Share

Shire plc, which partnered with New River Pharmaceuticals Inc. two years on a drug for attention deficit hyperactivity disorder, agreed to acquire the smaller firm for $2.6 billion in cash. (BioWorld Today) Read More

Lux Starts Phase III Studies; Isotechnika Raises $34.5M

Read More

New Autism Clues As Prevalence Estimates Increase Once Again

Read More

Caprion, Ecopia Merger Gets $45M Pledge From Investors

Read More

Theratechnologies Bringing In C$52.5M To Fund Phase III Trial

Read More

BioMarin Pharma Misses With Phase IIa Hypertension Trial

Read More

Other News To Note

Read More

Clinic Roundup

Read More